Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen
Firm News | March 3, 2026
Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc. The all-stock transaction is valued at approximately $300 million.
Our corporate team includes partners Branden Berns and Ryan Murr and associates Evan Shepherd, Lauren Navarro, Hunter Michielson, and Lauren Romagnoli. Partners Pamela Lawrence Endreny and Rachel Kleinberg and associate Elizabeth Johnson are advising on tax aspects, partner Bradley Smith is advising on antitrust aspects, partner David Wolber is advising on international trade aspects, and partner Sean Feller is advising on benefits.